Skip to main content
Log in

Safety of Telmisartan in Patients with Arterial Hypertension

An Open-Label Observational Study

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Objective: To determine whether age, gender, concomitant disease and/or previous or present antihypertensive medication affect the safety or antihypertensive efficacy of telmisartan in the treatment of arterial hypertension.

Study Design and Methods: In this large-scale, open-label postmarketing surveillance study, German physicians systematically documented their observations concerning patients with essential hypertension on case report forms. Patients were treated for 6 months with telmisartan (40–80mg once daily). Data were analysed using direct group comparisons and multiple linear regression analysis.

Results: A total of 19 870 patients (52.3% males, mean age 59.1 years) were evaluated, of whom 47.6, 18.3, 13.2 and 2.1%, respectively, had concomitant hypercholesterolaemia, diabetes mellitus, congestive heart failure and renal insufficiency. In the overall group, adverse events were reported in 1.9% of patients. Global tolerability was rated as very good, good, moderate or poor, respectively, in 74.7, 22.1, 0.7 and 0.5% of patients; tolerability was similar across all subgroups of patients. Telmisartan treatment did not increase serum creatinine or potassium in any subgroup, including >400 patients with impaired renal function (basal creatinine 1.73 mg/dL). Telmisartan had no adverse effects on glucose, triglyceride or cholesterol levels. In the overall group, telmisartan reduced mean ± SD systolic blood pressure from 171.3 ± 16.4mm Hg to 141.3 ± 12.0mm Hg and diastolic blood pressure from 99.0 ± 9.4mm Hg to 83.4 ± 6.9mm Hg. Reductions were very similar between genders, age groups and patients with and without comorbidities, and not dependent on prior or concomitant treatment with other antihypertensive drugs.

Conclusion: The safety and efficacy of telmisartan found in controlled studies is maintained in a large postmarketing population that included sizeable patient subgroups potentially at higher risk for adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Fig. 2

Similar content being viewed by others

References

  1. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens 2003; 5: 66–75

    Article  CAS  Google Scholar 

  2. Neal B, MacMahon S, Chapman S, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64

    Article  CAS  PubMed  Google Scholar 

  3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60

    Article  CAS  PubMed  Google Scholar 

  4. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  Google Scholar 

  5. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10

    Article  CAS  PubMed  Google Scholar 

  6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9

    Article  CAS  PubMed  Google Scholar 

  7. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8

    Article  CAS  PubMed  Google Scholar 

  8. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8

    Article  CAS  PubMed  Google Scholar 

  9. Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42

    Article  CAS  PubMed  Google Scholar 

  10. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001; 14(7 Pt 2): 231S–6S

    Article  CAS  PubMed  Google Scholar 

  11. Thurman JM, Schrier RW. Comparative effects of ACE inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003; 114: 588–98

    Article  CAS  PubMed  Google Scholar 

  12. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000; 58: 2084–92

    Article  CAS  PubMed  Google Scholar 

  13. Hannedouche T, Chanard J, Baumelou B, et al. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001; 2: 246–54

    Article  CAS  PubMed  Google Scholar 

  14. Leu JG, Huang CM, Kao SJ, et al. Efficacy and safety of losartan in patients with proteinuria. Nephron 2002; 91: 496–8

    Article  CAS  PubMed  Google Scholar 

  15. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5: 58–63

    Article  CAS  Google Scholar 

  16. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501–29

    Article  CAS  PubMed  Google Scholar 

  17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–72

    Article  CAS  PubMed  Google Scholar 

  18. Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15Suppl. 2: S67–75

    Article  CAS  Google Scholar 

  19. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–73

    Article  CAS  PubMed  Google Scholar 

  20. Atlas SA, Case DB, Sealey JE, et al. Interruption of the reninangiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979; 1: 274–80

    Article  CAS  PubMed  Google Scholar 

  21. Elms JJ. Potassium imbalance: causes and prevention. Postgrad Med 1982; 72: 165–71

    CAS  PubMed  Google Scholar 

  22. Maschio G. Protecting the residual renal function: how do ACE inhibitors and calcium antagonists compare? Nephron 1994; 67: 257–62

    Article  CAS  PubMed  Google Scholar 

  23. Cohn JN, Levine TB, Francis GS, et al. Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981; 102: 509–14

    Article  CAS  PubMed  Google Scholar 

  24. Mitas JA, O’Connor DT, Stone RA. Hypertension in renal insufficiency: a major therapeutic problem. Postgrad Med 1978; 64: 113–20

    PubMed  Google Scholar 

  25. Chalmers JP, Wing LM, West MJ, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension. Aust N Z J Med 1986; 16: 475–80

    Article  CAS  PubMed  Google Scholar 

  26. Morgan T, Carney S, Roberts R. Changes in plasma renin activity and blood pressure after acute and chronic administration of beta-adrenergic receptor-blocking drugs. Clin Sci Mol Med Suppl 1975; 2: 81s–3s

    CAS  PubMed  Google Scholar 

  27. Bauer JH, Sunderrajan S, Reams G. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. Am J Cardiol 1985; 56: 62H–7H

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This analysis is based on a study that has been funded by Boehringer Ingelheim. Dr Michel is a paid consultant of Boehringer Ingelheim, Drs Bohner and Koster are employees of Boehringer Ingelheim, and Dr Schafers is a paid lecturer of Bayer, which co-promotes telmisartan in Germany.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin C. Michel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michel, M.C., Bohner, H., Köster, J. et al. Safety of Telmisartan in Patients with Arterial Hypertension. Drug-Safety 27, 335–344 (2004). https://doi.org/10.2165/00002018-200427050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427050-00005

Keywords

Navigation